Mohd Khairuddin Md Arshad
Thumbnail Image
Preferred name
Mohd Khairuddin Md Arshad
Official Name
Mohd Khairuddin , Md Arshad
Alternative Name
Md. Arshad, M. K.
Arshad, Mohd K.M.
Arshad, M. K.M.
Khairuddin Md Arshad, Mohd
Arshad, M. K.Md
Main Affiliation
Scopus Author ID
57211870224
Researcher ID
L-5830-2013

Research Output

Filters

1
3
2 1
Reset filters

Settings
Now showing 1 - 3 of 3
  • Publication
    Immunosensing prostate-specific antigen: Faradaic vs non-Faradaic electrochemical impedance spectroscopy analysis on interdigitated microelectrode device
    ( 2020-11-01)
    Ibau, Conlathan
    ;
    Mohd Khairuddin Md Arshad
    ;
    Mohammad Nuzaihan Md Nor
    ;
    Subash Chandra Bose Gopinath
    ;
    Mohamad Faris Mohamad Fathil
    ;
    Shahidah Arina Shamsuddin
    This work explores Electrochemical Impedance Spectroscopy (EIS) detection for a highly-sensitive quantification of prostate-specific antigen (PSA) in Faradaic (f-EIS) and non-Faradaic modes (nf-EIS). Immobilization of monoclonal antibody specific to PSA (anti-PSA) was performed using 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride and N-hydroxysuccinimide crosslinking agents in order to conjugate carboxylic (-COOH) terminated group of 16-Mercaptoundecanoic acid with amine (-NH3+) on anti-PSA epitope. This approach offers simple and efficient approach to form a strong, covalently bound thiol-gold (S–Au) for a reliable SAM layer formation. Studies on the topographic of pristine Au-IDE surface were performed by Scanning Electron Microscopy and Energy Dispersive X-ray Spectroscopy techniques, meanwhile a 3-dimensional optical surface profiler, Atomic Force Microscopy and X-ray Photoelectron Spectroscopy techniques were used to validate the successful functionalization steps on the sensor transducer surface. Detection of PSA in f-EIS mode was carried out by measuring the response in charge transfer resistance (Rct) and impedance change (Z), meanwhile in nf-EIS mode, the changes in device capacitance was monitored. In f-EIS mode, the sensor reveals a logarithmic detection of PSA in a range of 100 ng/ml down to 0.01 ng/ml in Phosphate Buffered Saline with a recorded sensitivity of 2.412 kΩ/log10 ([PSA] ng/ml) and the limit of detection (LOD) down to 0.01 ng/ml. The nf-EIS detection mode yields a logarithmic detection range of 5000 ng/ml down to 0.5 ng/ml, with a sensitivity of 8.570 nF/log10 ([PSA] ng/ml) and an LOD of 0.5 ng/ml. The developed bio-assay yields great device stability, specificity to PSA and repeatability of detection that would pave its way for the future development into portable lab-on-chip bio-sensing system.
      10  27
  • Publication
    An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
    ( 2023)
    Adam Hussaini
    ;
    Subash Chandra Bose Gopinath
    ;
    Nor Azizah Parmin
    ;
    Tijjani Adam
    ;
    Mohd Khairuddin Md Arshad
    ;
    Husein Irzaman
    ;
    Uda Hashim
    In severe cases, Parkinson’s disease causes uncontrolled movements known as motor symptoms such as dystonia, rigidity, bradykinesia, and tremors. Parkinson’s disease also causes non-motor symptoms such as insomnia, constipation, depression and hysteria. Disruption of dopaminergic and non-dopaminergic neural networks in the substantia nigra pars compacta is a major cause of motor symptoms in Parkinson’s disease. Furthermore, due to the difficulty of clinical diagnosis of Parkinson’s disease, it is often misdiagnosed, highlighting the need for better methods of detection. Treatment of Parkinson’s disease is also complicated due to the difficulties of medications passing across the blood–brain barrier. Moreover, the conventional methods fail to solve the aforementioned issues. As a result, new methods are needed to detect and treat Parkinson's disease. Improved diagnosis and treatment of Parkinson's disease can help avoid some of its devastating symptoms. This review explores how nanotechnology platforms, such as nanobiosensors and nanomedicine, have improved Parkinson’s disease detection and treatment. Nanobiosensors integrate science and engineering principles to detect Parkinson’s disease. The main advantages are their low cost, portability, and quick and precise analysis. Moreover, nanotechnology can transport medications in the form of nanoparticles across the blood–brain barrier. However, because nanobiosensors are a novel technology, their use in biological systems is limited. Nanobiosensors have the potential to disrupt cell metabolism and homeostasis, changing cellular molecular profiles and making it difficult to distinguish sensor-induced artifacts from fundamental biological phenomena. In the treatment of Parkinson’s disease, nanoparticles, on the other hand, produce neurotoxicity, which is a challenge in the treatment of Parkinson’s disease. Techniques must be developed to distinguish sensor-induced artifacts from fundamental biological phenomena and to reduce the neurotoxicity caused by nanoparticles.
      7  17
  • Publication
    Integration of microfluidic channel on electrochemical-based nanobiosensors for monoplex and multiplex analyses: An overview
    ( 2023)
    Adam Hussaini
    ;
    Subash Chandra Bose Gopinath
    ;
    Mohd Khairuddin Md Arshad
    ;
    Tijjani Adam
    ;
    Uda Hashim
    ;
    Zaliman Sauli
    ;
    Fakhri Makram A.
    ;
    Subramaniam Sreeramanan
    ;
    Chen Yeng
    ;
    Sasidharan Sreenivasan
    ;
    Wu Yuan Seng
    Background: Microfluidic devices have evolved into low-cost, simple, and powerful analytical tool platforms. Herein, an electrochemically-based microfluidic nanobiosensor array for monoplex and multiplex detection of physiologically relevant analytes is reviewed. Unlike other analyte detection methods, microfluidics-based embedded electrochemical nanobiosensors are portable, custom electrochemical readers for signal reading. Methods: Microfluidic devices and electrochemical sensors can be integrated into monoplex or multiplex systems. The integrated system is simple to use and sensitive, and so has great potential as a powerful tool for profiling immune-mediated treatment responses in real time. It may also be developed further as a point-of-care diagnostic device for conducting near-patient tests using biological samples. Therefore, using mutiplex analysis, a biosensor array may detect multiple analytes in a sample solution and provide different outputs for each analyte. A microfluidic electrochemical nanobiosensor, for example, can detect urine glucose, lactate, and uric acid. The microfluidic array of integrated nanobiosensors and electrochemical sensors enables fast and cost-effective selection of high-quality and statistically significant diagnostic data at the point of care. The multiplex analytical test is an important molecular tool for academic research as well as clinical diagnosis. Although key approaches for analysing numerous analytes have been developed, none of them are suitable for point-of-care diagnostics, especially in situations with limited resources. Significant findings: In this study, monoplex and multiplex microfluidic assays for rapid measurement of single and multiple analytes at the point of care are presented. Since this test can analyse both single and multiple analytes, it is exceptionally specific, easy to use, and inexpensive. The ability of integrated electrochemical-based microfluidic devices with single channel and multiple channels systems to perform monoplex and multiplex analysis simultaneously and independently is the novelty of this review.
      2